Latest News and Press Releases

Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D virusesInitial clinical data...

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral...

--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a liver-focused approach to improve tolerability-- SOUTH SAN FRANCISCO, Calif., Nov. 10,...

Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyondNow anticipate four development candidates from expanded pipeline in clinical...

-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN...

-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 ...

− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected – − Progression into clinical studies...

-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist...

Herpesvirus candidate ABI-5366 anticipated to enter clinic in first half of 2024New data for several pipeline programs presented at IHW and EASL 2023Additional development candidate nomination...

-- First presentation of preclinical data describing the activity, pharmacokinetics and safety profile of ABI-5366, supporting planned clinical entry in 1H 2024 -- SOUTH SAN FRANCISCO, Calif.,...